Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKLR | P30613 | 3/20 | 0.69 |
| ▸ | KDR | P35968 | 3/20 | 0.53 |
| ▸ | GALNT2 | Q10471 | 2/20 | 0.53 |
| ▸ | GALNT1 | Q10472 | 1/20 | 0.53 |
| ▸ | GALNT3 | Q14435 | 1/20 | 0.53 |
| ▸ | GALNT10 | Q86SR1 | 1/20 | 0.53 |
| ▸ | GALNT13 | Q8IUC8 | 1/20 | 0.53 |
| ▸ | GALNT6 | Q8NCL4 | 1/20 | 0.53 |
| ▸ | GALNT14 | Q96FL9 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 6/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | HPGD | P15428 | 5/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26768122 | 0.89 | PKLR (0.57) | PKLRKDRGALNT2GALNT1GALNT3 | |
| SCHEMBL31440682 | 0.86 | PKLR (0.54) | PKLRKDRGALNT2GALNT1GALNT3 | |
| SCHEMBL27210072 | 0.86 | PKLR (0.54) | PKLRKDRGALNT2GALNT1GALNT3 | |
| SCHEMBL29369342 | 0.82 | PKLR (1.00) | PKLRGALNT2GALNT1GALNT3GALNT10 | |
| SCHEMBL15423100 | 0.82 | PKLR (1.00) | PKLRGALNT2GALNT1GALNT3GALNT10 | |
| SCHEMBL3887841 | 0.80 | KDR (0.54) | PKLRKDRLMNAMCL1KDM4E | |
| SCHEMBL7971098 | 0.79 | PKLR (0.66) | PKLRGALNT2GALNT1GALNT3GALNT10 | |
| SCHEMBL27617272 | 0.78 | HSD17B3 (0.61) | PKLRKDRMCL1KDM4EHPGD | |
| SCHEMBL2318335 | 0.76 | MAOA (0.66) | PKLRKDRMCL1KDM4EHPGD | |
| SCHEMBL28836089 | 0.75 | KDM4E (0.61) | PKLRKDRLMNAPPARGNCOA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024025953-A2 | THERAPEUTIC USES OF UROLITHIN DERIVATIVES | VANDRIA SA (CH) | 2024-02-01 | — | — | WO | disclosed |
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2023-11-21 | — | — | US | disclosed |
| WO-2023031673-A1 | TREATING LONG COVID-19 WITH UROLITHINS | AMAZENTIS SA (CH) | 2023-03-09 | — | — | WO | disclosed |
| US-6194439-B1 | ANTICANCER AGENT | PFIZER INC. | 2001-02-27 | — | — | US | disclosed |
| EP-0586608-A1 | TRICYCLIC POLYHYDROXYLIC TYROSINE KINASE INHIBITORS | PFIZER INC. (US) | 1994-03-16 | — | — | EP | disclosed |
| WO-1992021660-A1 | TRICYCLIC POLYHYDROXYLIC TYROSINE KINASE INHIBITORS | PFIZER, INC. (US) | 1992-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | PKLR 1783/4885KDR 4841/4885GALNT2 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.